拉米夫定联合复方鳖甲软肝片对乙肝纤维化的影响

Clinical research of Lamivudine combined with Fufangbiejiaruangan tablets on treating hepatic fibrosis following chronic hepatitis B

目的观察拉米夫定联合复方鳖甲软肝片治疗乙型肝炎肝纤维化的疗效。方法将80例乙型肝炎肝纤维化患者随机分为治疗组和对照组。治疗组患者用拉米夫定和复方鳖甲软肝片口服，对照组患者采用拉米夫定治疗，疗程1年。观察并比较两组患者治疗前后的肝功能、肝纤维化指标及HBV-DNA定量检测指标等的变化。结果治疗组治疗后AST、TBi1、HA等较治疗前有明显改善，且显著优于对照组（P〈0．05-0．01），差异有显著性；HBV-DNA定量变化治疗前后比有显著的统计学差异（P〈0．05），但两组相比较差异无显著性意义。结论拉米夫定联合复方鳖甲软肝片能够通过抑制病毒和抗肝纤维化，明显改善乙型肝炎肝纤维化患者的病情。

Objective To observe the therapeutic effect of Lamivudine combined with Fufangbiejiaruangan tablets on treating hepatic fibrosis following chronic hepatitis B. Methods 80 cases of hepatic fibrosis following chronic hepatitis B were divided randomly into treatment group and control group. The treatment group was treated by Lamivudine combined with Fufangbiejiaruangan tablets orally. The Control group was treated by Lamivudine only, both for 12 months of therapy. Liver function, liver fibrosis, quantification of HBV DNA were tested before and after therapy. Results After treatment the AST, Tbil, HA levels of the treatment group were improved obviously compared with that of before treatment and control group. There were no significant difference in quantitative detection of serum HBV-DNA between the treatment group and control group. Conclusions The treatment of Lamivudine combined with Fufangbiejiaruangan tablets might improved patients condition depended on antivirus and antifibrosis.